These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35878723)

  • 21. Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction.
    Yarnykh VL; Krutenkova EP; Aitmagambetova G; Repovic P; Mayadev A; Qian P; Jung Henson LK; Gangadharan B; Bowen JD
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):618-625. PubMed ID: 29439122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcortical gray matter segmentation and voxel-based analysis using transverse relaxation and quantitative susceptibility mapping with application to multiple sclerosis.
    Cobzas D; Sun H; Walsh AJ; Lebel RM; Blevins G; Wilman AH
    J Magn Reson Imaging; 2015 Dec; 42(6):1601-10. PubMed ID: 25980643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron deposition of the deep grey matter in patients with multiple sclerosis and neuromyelitis optica: a control quantitative study by 3D-enhanced susceptibility-weighted angiography (ESWAN).
    Chen X; Zeng C; Luo T; Ouyang Y; Lv F; Rumzan R; Wang Z; Li Q; Wang J; Hou H; Huang F; Li Y
    Eur J Radiol; 2012 Apr; 81(4):e633-9. PubMed ID: 22280874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
    Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
    Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome.
    Al-Radaideh AM; Wharton SJ; Lim SY; Tench CR; Morgan PS; Bowtell RW; Constantinescu CS; Gowland PA
    Mult Scler; 2013 Jun; 19(7):896-903. PubMed ID: 23139386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Hyun JW; Park G; Kwak K; Jo HJ; Joung A; Kim JH; Lee SH; Kim S; Lee JM; Kim SH; Kim HJ
    Eur J Neurol; 2017 Feb; 24(2):437-445. PubMed ID: 28009104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional quantitative susceptibility mapping from standard fMRI studies.
    Sun H; Seres P; Wilman AH
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 27687150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
    Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
    Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.
    Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A
    AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.
    Zivadinov R; Tavazzi E; Bergsland N; Hagemeier J; Lin F; Dwyer MG; Carl E; Kolb C; Hojnacki D; Ramasamy D; Durfee J; Weinstock-Guttman B; Schweser F
    Radiology; 2018 Nov; 289(2):487-496. PubMed ID: 30015589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis.
    Ceccarelli A; Rocca MA; Perego E; Moiola L; Ghezzi A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2011 Jun; 17(6):702-7. PubMed ID: 21228024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum iron concentration is associated with subcortical deep gray matter iron levels in multiple sclerosis patients.
    Bergsland N; Agostini S; Laganà MM; Mancuso R; Mendozzi L; Tavazzi E; Cecconi P; Clerici M; Baglio F
    Neuroreport; 2017 Aug; 28(11):645-648. PubMed ID: 28509815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of MRI T1 Hypointense Brain Lesions on Cerebral Deep Gray Matter Volume Measures in Multiple Sclerosis.
    Buyukturkoglu K; Mormina E; De Jager PL; Riley CS; Leavitt VM
    J Neuroimaging; 2019 Jul; 29(4):458-462. PubMed ID: 30892794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron and volume in the deep gray matter: association with cognitive impairment in multiple sclerosis.
    Modica CM; Zivadinov R; Dwyer MG; Bergsland N; Weeks AR; Benedict RH
    AJNR Am J Neuroradiol; 2015 Jan; 36(1):57-62. PubMed ID: 24948507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study.
    Zivadinov R; Schirda C; Dwyer MG; Haacke ME; Weinstock-Guttman B; Menegatti E; Heininen-Brown M; Magnano C; Malagoni AM; Wack DS; Hojnacki D; Kennedy C; Carl E; Bergsland N; Hussein S; Poloni G; Bartolomei I; Salvi F; Zamboni P
    Int Angiol; 2010 Apr; 29(2):158-75. PubMed ID: 20351672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron deposition in the gray matter in patients with relapse-remitting multiple sclerosis: A longitudinal study using three-dimensional (3D)-enhanced T2*-weighted angiography (ESWAN).
    Du S; Sah SK; Zeng C; Wang J; Liu Y; Xiong H; Li Y
    Eur J Radiol; 2015 Jul; 84(7):1325-32. PubMed ID: 25959392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
    de Ruiter LRJ; Loonstra FC; Jelgerhuis JR; Coerver EME; Toorop AA; van Leeuwen ICE; Noteboom S; Moraal B; Strijbis EMM; Schoonheim MM; Uitdehaag BMJ
    Mult Scler Relat Disord; 2023 Mar; 71():104568. PubMed ID: 36805177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping.
    Bilgic B; Pfefferbaum A; Rohlfing T; Sullivan EV; Adalsteinsson E
    Neuroimage; 2012 Feb; 59(3):2625-35. PubMed ID: 21925274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.